A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
In brief
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content * How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times
Key facts
- Study ID
- NCT06836609
- Run by
- Regeneron Pharmaceuticals
- People needed
- 132
- Starts
- 2025-04-28
- Expected to finish
- 2027-05-15
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Liver Health — Chandler, Arizona, United States (enrolling)
- Adobe Clinical Research — Tucson, Arizona, United States (enrolling)
- Richmond Pharmacology Limited — London, Greater London, United Kingdom (enrolling)
- Parexel International Early Phase Clinical Unit — Harrow, London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.